
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
GENSIGHT BIOLOG. EO -,025 G49N FR0013183985 BAW/UFN
© 2024 Xetra Newsboard
Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,234 | 0,237 | 16:29 | |
0,234 | 0,237 | 16:23 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | GenSight Biologics Annual General Meeting on May 13, 2025 | Procedures for obtaining preparatory documents for the General Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused... ► Artikel lesen | |
08.04. | GenSight Biologics S.A.: GenSight Biologics Announces the Filing of its 2024 Universal Registration Document | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
07.04. | GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update |
Operations funded until early June 2025 as a result of disciplined spending controls
Discussions with French agency ANSM regarding the early access program (AAC) for LUMEVOQ progressing
... ► Artikel lesen | |
19.03. | GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen | |
17.03. | GenSight Biologics Announces LUMEVOQ Scientific Updates at NANOS 2025 | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative... ► Artikel lesen |